Journal Article

Design and rationale of a pragmatic randomized clinical trial of early dronedarone versus usual care to change and improve outcomes in persons with first-detected atrial fibrillation – the CHANGE AFIB study

Pokorney, Sean D., Chiswell, Karen, Miller, Joseph B., Frankel, David S., Rashkin, Jason, Kirchhof, Paulus, Elkind, Mitchell S.V., Nemeth, Hayley, Rutan, Christine, Fonarow, Gregg C., Fermann, Gregory J., Calkins, Hugh, Fontaine, John M., Allyn, Nadine, Steinberg, Benjamin A., Blanco, Rosalia, Piccini, Jonathan P., Butler, Javed, Russo, Andrea M., Gale, Rex, Koren, Andrew, Kalscheur, Matthew, Albert, Christine

2025

Overview

While there are several completed clinical trials that address treatment strategies in patients with symptomatic and recurrent atrial fibrillation (AF), there are no randomized clinical trials that address first-line rhythm control of new-onset AF. Recent data suggest that early initiation of rhythm control within 1 year can improve outcomes. In this open-label pragmatic clinical trial nested within the Get with The Guidelines Atrial Fibrillation registry, approximately 3,000 patients with first-detected AF will be enrolled at approximately 200 sites. Participants will be randomized (1:1) to treatment with dronedarone in addition to usual care versus usual care alone. The primary endpoint will be time to first cardiovascular (CV) hospitalization or death from any cause through 12 months from randomization. Secondary endpoints will include a WIN ratio (all-cause death, ischemic stroke or systemic embolism, heart failure hospitalization, acute coronary hospitalization), CV hospitalization, and all-cause mortality. Patient reported outcomes will be analyzed based on change in Atrial Fibrillation Effect on Quality of Life (AFEQT) and change in Mayo AF-Specific Symptom Inventory (MAFSI) from baseline to 12 months. CHANGE AFIB will determine if treatment with dronedarone in addition to usual care is superior to usual care alone for the prevention of CV hospitalization or death from any cause in patients with first-detected AF. The trial will also determine whether initiation of rhythm control at the time of first-detected AF affects CV events or improves patient reported outcomes. - NCT05130268

• Publisher: Elsevier Inc,Elsevier Limited
• Subject: Ablation / Anti-Arrhythmia Agents - therapeutic use / Antiarrhythmics / Atrial Fibrillation - drug therapy / Beta blockers / Cardiac arrhythmia / Cause of Death - trends / Clinical medicine / Clinical trials / Congestive heart failure / Contraindications / Creatinine / Data collection / Death / Dronedarone - therapeutic use / Drug dosages / Embolism / FDA approval / Female / Fibrillation / Heart failure / Hospitalization / Humans / Ischemia / Male / Mortality / Multicenter Studies as Topic / Patients / Pragmatic Clinical Trials as Topic / Quality of Life / Randomization / Randomized Controlled Trials as Topic / Rhythm / Stroke / Time Factors / Treatment Outcome